Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
The East Coast investor will primarily provide debt financing to enable companies to reach milestones with minimal equity dilution.
Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.
Mount Sinai researchers showed that in male mouse models of heart attack, Cdx2 placental cells regenerated damaged tissue.
The Medicines Company announced long-term data for inclisiran, showing that the drug lowered “bad” LDL cholesterol by more than 50%.
On the heels of a $120 million verdict issued last month, J&J was ordered by a Philadelphia jury to pay $80 million to a woman whose mesh eroded.
Computing-enabled R&D shop Schrödinger will use its $110 million haul to advance its nascent pipeline of wholly owned drugs.
Acutus Medical will acquire Rhythm Xience alongside a handful of new partnerships as expands its portfolio beyond its heart mapping platform.
The pipeline of drugs and vaccines aimed at diseases prevalent in low- and middle-income countries has more than doubled since 2014.
The FDA warned diabetes patients of the risks of using homegrown treatment devices, such as unrecognized combos of CGMs and insulin pumps.
British biotech is often a disregarded backwater in life sciences, but today a host of good news has shone the spotlight back onto its potential.